Business — Page 16

Nurix Therapeutics shares extended losses from after Tuesday’s market close into Wednesday premarket trading.

Total revenue was $25.752 million, and GAAP net loss per share was $0.81 on both basic and diluted bases.

The planned sale adds a euro target to a wider cross-border financing effort with a combined target of at least $20 billion.

Revenue totaled $44.82 million for the quarter, down 10.2% year over year.

Revenue rose 9.7% to $768.538 million, while digital-only subscription revenue increased 14.6%.

Royalty Receipts rose to $883 million, while net income attributable to the company fell to $144.7 million.

Global comparable sales rose 1.5%, accelerating from 1.2% growth in the second quarter.

The retailer earned $62 million in the third quarter, while international net revenue fell 2.3% to $380 million.

The company also lowered its 2026 Automotive segment margin outlook to a range from a 0.5% loss to a 0.5% profit.

Revenue totaled $195.3 million, $33.3 million above estimates.

The division will combine spot and block trades, financing, derivatives and settlement, with Pete Janney, a former NYDIG executive, leading it.

Revenue increased 11.3% from a year earlier, while funds from operations reached $0.51 per limited partnership unit.

The decline followed a 3.4% increase in the prior week.

Early investors reduced the company’s valuation to about $35 billion earlier this year.

Revenue topped analyst forecasts of $14.67 billion to $14.74 billion, while adjusted EPS fell below estimates of $0.86 to $0.91.

Non-GAAP EPS was $1.86, 1 cent above estimates, while revenue exceeded forecasts by $80 million.

Civil aero engines, defense and nuclear energy contributed to the increase.

Revenue was $520.1 million, down from $552.2 million in the year-earlier period and $22.72 million below estimates.

The company had $5.1 million in unrestricted cash at quarter-end; management concluded there was substantial doubt about its ability to continue as a going concern during the next year.

Comparable-store sales rose 4.1%, while non-GAAP earnings per share came in at $0.38, $0.04 below estimates.

Net income attributable to the partnership was $16.219 million, while total net sales reached $314.459 million.

Earnings Available for Distribution totaled $6.632 million, while book value fell to $9.27 per share and the company declared a $0.24 dividend.

Diluted earnings per share declined 20% to $5.71, while research and development expense more than doubled to $279.2 million.

Higher kilowatt sales and lower depreciation expense drove the gain, while year-to-date fuel cost savings for customers totaled $9.9 million.

Net income fell to $29.7 million from $101.7 million, though the earlier quarter included a discrete $77.9 million tax benefit.

The filing follows smaller workforce reductions in December 2024 and July 2023.

The company set its GAAP diluted EPS outlook at at least $6.98, replacing a range of $6.84 to $7.04. Third-quarter revenue rose 5.3% year over year to $108.4 billion.

Aetna and CVS Caremark would remain together in a separate company, with the separation expected in the first half of 2028.

Hut 8 generated $175.4 million in net proceeds and spent $175.3 million on repurchases. Its board raised the total buyback authorization to $1 billion in November.

Pierre Computer’s technology is already integrated into Codex as AI agents take on more programming work.

Paolo Ardoino argued that the practice could pose significant risks to market integrity.

The amount matches the Sept. 1 payment and leaves Enbridge’s 2026 annualized dividend at C$3.88 per share.

Average USDC circulation rose 8% to $73.3 billion, while an ARC token presale contributed to higher other revenue.

The company generated C$237 million in funds flow from operations and more than C$90 million in free cash flow.

Commitments from 13 listed companies and affiliated investment entities totaled 3.495 billion yuan, about 46.48% of the fund.

GAAP earnings per share were $0.06. Taboola projected fourth-quarter revenue of $477 million to $493 million.

Third-quarter revenue reached $891 million, while GAAP earnings per share were $0.46.

GAAP earnings per share were $0.83. Full-year consolidated net sales guidance remains approximately $2.65 billion to $2.675 billion.

Third-quarter non-GAAP EPS reached $2.31, while revenue was $3.7 billion, down 0.6% from a year earlier.

Revenue increased 21.2% from a year earlier but fell from C$17.4 billion in the second quarter of 2026.